FTC and Senate back reverse payment ban
Representatives of the Federal Trade Commission and the Department of Justice on Thursday questioned the concept of settlement agreements between generic and brand drug companies, claiming that they eliminate the ability to evaluate the patent validity of a potentially important drug
Ironically, this should be troubling to patent lawyers too, said Will Tom, General Counsel of the FTC.
He added that such agreements also encourage frivolous challenges to strong patents.
Tom spoke during a joint meeting of...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.